secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2026-03-06T23:59:59+00:00
Accession:  0001213900-26-024777
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix reaffirms FY2027 DefenCath guidance $100M-$140M; FY2026 revenue guidance $300M-$320M
--------------------------------------------------------------------------------

- Reaffirms FY2027 DefenCath sales $100M-$140M, correcting inadvertent $100M-$125M range from March 5 earnings call.
- FY2026 guidance: revenue $300M-$320M, adjusted EBITDA $100M-$125M, DefenCath sales $150M-$170M.
- Q4 2025 net revenue $129M, DefenCath sales $91M; FY2025 pro forma net revenue $401M.
- Pipeline milestones: REZZAYO prophylaxis Ph3 data expected Q2 2026; DefenCath TPN (NUTRI-LOCK) data 1H 2027.
- Balance sheet at Dec 31 2025: cash & short-term investments $149M, convertible debt $150M, shares outstanding 79.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390026024777/0001213900-26-024777-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390026024777/ea0280394-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-024777

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer